KOMO Biosciences appoints Martin Meeson to its Board of Directors
– USA, MA – KOMO Biosciences, Inc., a next-generation precision genome engineering technology company, announced the appointment of Martin Meeson to its Board of Directors, bringing more than two decades of industry leadership, which will be invaluable as KOMO continues to commercialize its genome engineering technology.…